BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23073619)

  • 41. NK-Cell Lymphomas.
    Chihara D; Oki Y
    Cancer Treat Res; 2019; 176():163-184. PubMed ID: 30596218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK/T-cell lymphoma arising in the lungs.
    Tajima S; Takanashi Y; Koda K; Fukayama M
    Pathol Int; 2015 Dec; 65(12):661-5. PubMed ID: 26459854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of extranodal natural killer/t-cell lymphoma, nasal type.
    Chaudhary RK; Bhatt VR; Vose JM
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):245-52. PubMed ID: 25659751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.
    Kohrt H; Advani R
    Leuk Lymphoma; 2009 Nov; 50(11):1773-84. PubMed ID: 19883307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
    Ghione P; Qi S; Imber BS; Seshan V; Moskowitz A; Galasso N; Lunning M; Straus D; Sauter C; Dahi P; Dogan A; Yahalom J; Horwitz S
    Leuk Lymphoma; 2020 Dec; 61(14):3331-3341. PubMed ID: 32844695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of early diagnosis on the prognosis of extranodal NK/T-cell lymphoma with massive lung involvement: a case report.
    Yabushita T; Yoshioka S; Furumiya T; Nakamura M; Yamashita D; Imai Y; Ishikawa T
    BMC Pulm Med; 2019 Feb; 19(1):48. PubMed ID: 30791900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
    Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
    J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.
    Wang L; Xia ZJ; Huang HQ; Lu Y; Zhang YJ
    Int J Hematol; 2012 Nov; 96(5):617-23. PubMed ID: 22983648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of extranodal NK/T-cell lymphoma, nasal type mimicking typical manifestations of adult-onset Still's disease (AOSD) with hemophagocytic syndrome: diagnostic consideration between malignant lymphoma without lymphadenopathy and AOSD.
    Kato T; Tanabe J; Kanemoto M; Kobayashi C; Morita S; Karahashi T
    Mod Rheumatol; 2009; 19(6):675-80. PubMed ID: 19609486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
    Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
    Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
    Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type.
    Wang KF; Chang BY; Chen XQ; Liu PP; Wuxiao ZJ; Wang ZH; Li S; Jiang WQ; Xia ZJ
    Med Oncol; 2014 Dec; 31(12):318. PubMed ID: 25377661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
    Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
    J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
    Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
    Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.
    Suzuki R; Suzumiya J; Yamaguchi M; Nakamura S; Kameoka J; Kojima H; Abe M; Kinoshita T; Yoshino T; Iwatsuki K; Kagami Y; Tsuzuki T; Kurokawa M; Ito K; Kawa K; Oshimi K;
    Ann Oncol; 2010 May; 21(5):1032-40. PubMed ID: 19850638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.
    Nomura E; Isoda K; Yamanaka K; Yamaguchi M; Hakamada A; Mizutani H
    J Dermatol; 2005 Mar; 32(3):204-9. PubMed ID: 15863868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current management of nasal NK/T-cell lymphoma.
    Au WY
    Oncology (Williston Park); 2010 Apr; 24(4):352-8. PubMed ID: 20464847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type.
    Zheng Y; Yang C; Liang T; Yang D; Liu Z
    Hematol Oncol; 2020 Feb; 38(1):103-105. PubMed ID: 31102421
    [No Abstract]   [Full Text] [Related]  

  • 60. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.